- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05656131
Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer
Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer,A Two-cohort, Open, Multicenter,Phase II Study
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: shusen Wang
- Phone Number: +8613926168469
- Email: wangshs@sysucc.org.cn
Study Contact Backup
- Name: jingmin Zhang
- Phone Number: +8618826246924
- Email: zhangjm1@sysucc.org.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Recruiting
- Sun-Yat Sen University Cancer Center
-
Contact:
- jingmin Zhang
- Phone Number: +8618826246924
- Email: zhangjm1@sysucc.org.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women ≥18 years old
- Histologically or cytologically confirmed locally advanced or metastatic breast cancer.
- Pathologically documented breast cancer that is HER2-negative for both primary tumor and metastases (if puncture results are available)
- ECOG PS of 0-1.
- For locally advanced or metastatic breast cancer, the tumor tissue HRD score> 42 is needed (for HRD testing, the recipient must provide a test report from an institution with a qualified testing unit prior to enrollment; if no report is available, the relevant test sample must be provided for confirmation in the central laboratory prior to enrollment).
- Presence of at least 1 measurable lesion based on computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1).
- If treated with PARP inhibitors or immune checkpoint inhibitors in the (neo) adjuvant phase, a relapse-free interval of more than 1 year after the end of treatment is required.
- Prior treatment with paclitaxel-based chemotherapeutic agents is allowed.
- ≤ 2 lines of prior chemotherapy in the advanced stage.
- For HR+ patients, progression within two years of (neo) adjuvant endocrine therapy is required; patients who have progressed after more than two years of endocrine therapy are required to have received at least first-line endocrine therapy for metastatic disease (including CDK4/6 inhibitors, cidarabine and PI3K inhibitors, etc.).
- ≤ grade 1 (CTCAE v5.0) for all toxicities occurring in relation to prior antitumor therapy. However, patients with any grade of alopecia are allowed to enter the study.
CNS metastases without symptoms may be enrolled.
- If there is no extracranial assessable lesion, intracranial lesions are required to be assessable and suitable for systemic therapy only
- If there is an extracranial evaluable lesion, patients with an intracranial lesion that has been stabilized with local therapy may be accepted for enrollment
Routine blood tests within 1 week prior to enrollment are essentially normal.
- White blood cell count (WBC) ≥ 2.5 × 109/L.
- Neutrophil count (ANC) ≥ 1.5 × 109/L.
- Platelet count (PLT) ≥ 75 × 109/L.
- Patients may receive blood transfusions or erythropoietin therapy to meet this criterion.
Basic normal liver and renal function tests within 1 week prior to enrollment.
- Total bilirubin (T BIL) ≤ 1.5 x the upper limit of normal (ULN).
- Glutathione transaminase (SGPT/ALT) ≤ 2.5 x ULN (≤ 5 x ULN in patients with liver metastases).
- Glutathione aminotransferase (SGOT/AST) ≤ 2.5× ULN (≤ 5× ULN in patients with liver metastases).
- creatinine clearance (Ccr) ≥ 60 ml/min.
- Patients subjects of reproductive/childbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and after the last dose of treatment medicine for at least 90 days.
- A life expectancy of at least 12 weeks.
- Patients must be able to participate and comply with treatment and follow-up.
Exclusion Criteria:
- Has multiple primary malignancies and requires standardized treatment or major surgery within 2 years of the first dose of study treatment.
- Treated with PARP inhibitors in advanced stages.
- BRCA1/2 germline mutation.
- Symptomatic or unstable brain metastases.
- Any severe or poorly controlled systemic disease such as poorly controlled hypertension, active bleeding susceptibility or active infection, as judged by the investigator. Chronic disease needs to be excluded.
- Refractory nausea, vomiting or chronic gastrointestinal disease, inability to swallow study drug or previous extensive bowel resection that may interfere with adequate absorption of PARP inhibitors.
- Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie, interstitial lung disease, pulmonary emboli within three months of the study enrollment, severe asthma, severe chronic obstructive pulmonary disease [COPD], restrictive lung disease, pleural effusion etc), and any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement (ie, rheumatoid arthritis, Sjögren's, sarcoidosis etc), or prior pneumonectomy.
- Otherwise considered inappropriate for the study by the Investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: fluzoparib
Fluzoparib: 150 mg twice daily (morning and evening) for 21 consecutive days as a cycle until disease progression or intolerance.
|
Arms A will be treated with fluzoparib alone
|
Experimental: fluzoparib+Camrelizumab
Fluzoparib: 150 mg twice daily (morning and evening) for 21 consecutive days as a cycle until disease progression or intolerance. Camrelizumab: 200 mg IV drip over approximately 30 minutes (no less than 20 minutes and no more than 60 minutes) on Day 1 of each 3-week treatment cycle until disease progression or intolerance. |
Arms B will be treated with fluzoparib in combination with camrelizumab
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate
Time Frame: Up to 3 years
|
Objective response is defined as a complete response (CR) or partial response (PR) according to RECIST v.1.1.recorded
from randomization until disease progression or death due to any cause
|
Up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progress-free survival
Time Frame: Up to 3 years
|
Time from randomization to the first documentation of objective tumor progression or to death due to any cause
|
Up to 3 years
|
Overall Survival
Time Frame: Up to 3 years
|
Time from randomization to date of death due to any cause.
according to the RECIST version 1.1 recorded in the time period between randomization and disease progression or death to any cause.
|
Up to 3 years
|
QoL questionnaire (quality of life)
Time Frame: Up to 3 years
|
Up to 3 years
|
|
Adverse effect (AE)
Time Frame: Up to 3 years
|
Any adverse effect occurred in the treatment
|
Up to 3 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MA-BC-II-042
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
-
Tianjin Medical University Cancer Institute and...RecruitingAdvanced HER2 Negative Breast Carcinoma | HRD+Breast CancerChina
-
National Cancer Institute (NCI)Active, not recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Unresectable Breast Carcinoma | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma | Metastatic HER2-Negative Breast Carcinoma | Unresectable HER2-Negative Breast Carcinoma | Locally Advanced HER2-Negative...United States
-
Zhejiang Cancer HospitalJiangsu Hengrui Pharmaceutical Co., Ltd.Not yet recruitingFemale Breast Cancer Patients | Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer | HRD Positive Advanced Breast Cancer
-
AIO-Studien-gGmbHNovartis Pharmaceuticals; iOMEDICO AGCompletedHer2-negative Metastatic Breast Cancer | Her2-negative Locally Advanced Breast CancerGermany
-
University of WashingtonBreast Cancer Research FoundationNot yet recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic HER2-Negative Breast Carcinoma | Metastatic Hormone Receptor-Positive Breast Carcinoma | Locally Advanced Unresectable HER2-Negative Breast Carcinoma | Locally Advanced Unresectable Hormone Receptor-Positive...United States
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
HutchmedActive, not recruitingRectal Cancer | Advanced Solid Tumors | Metastatic Breast Cancer | Triple Negative Breast Cancer | Metastatic Colon Cancer | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast CancerUnited States
-
Antonio Giordano, MDCardiff OncologyRecruitingBreast Cancer | Metastatic Breast Cancer | Inflammatory Breast Cancer | Invasive Breast Cancer | Locally Advanced Breast Cancer | Unresectable Breast Carcinoma | HER2-negative Breast Cancer | Triple Negative Breast Cancer (TNBC) | Hormone Receptor Negative Breast Carcinoma | Hormone Receptor/Growth Factor...United States
-
Olema Pharmaceuticals, Inc.RecruitingBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | HER2 Negative Breast Carcinoma | ER Positive Breast CancerKorea, Republic of, United States, Australia, Hong Kong, Taiwan, Malaysia, Thailand
-
Fudan UniversityRecruitingBreast Cancer | Breast Neoplasm | Breast Tumors | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer | Triple-Negative Breast Cancer (TNBC)China
Clinical Trials on Fluzoparib
-
Tianjin Medical University Cancer Institute and...RecruitingAdvanced HER2 Negative Breast Carcinoma | HRD+Breast CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.UnknownAdvanced Pancreatic CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Peking University People's HospitalJiangsu Hengrui Pharmaceutical Co., Ltd.Enrolling by invitationGermline BRCA-mutated HER2-negative Breast CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHealthy Adult SubjectsChina
-
Jiangsu HengRui Medicine Co., Ltd.307 Hospital of PLA; Peking University Cancer Hospital & InstituteCompletedAdvanced Solid MalignanciesChina
-
Atridia Pty Ltd.Completed
-
Atridia Pty Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.CompletedSmall Cell Lung CancerChina